Reentry/Rehabilitation

RSS Feed for this category

Drug Policy Prospects on Capitol Hill This Year [FEATURE]

There are nearly two dozen pieces of drug policy-related legislation pending on Capitol Hill, but given a bitterly divided Congress intently focused on the economic crisis and bipartisan warfare in the run-up to the 2012 election, analysts and activists are glum about the prospects for passing reform bills and even gloomier about the prospects for blocking new prohibitionist bills.

uphill climb for reform this year
But while drug reform in the remainder of the 112th Congress may take on the aspect of slow-moving trench warfare, there is work to be done and progress to be made, advocates interviewed by Drug War Chronicle said. And intensely expressed congressional concern over federal budget deficits could provide opportunities to take aim at the federal drug war gravy train.

Bills to reform drug policy or of relevance to drug policy reform this session run the gamut from hemp legalization, medical marijuana reforms, and marijuana legalization to various sentencing reform and ex-offender re-entry measures, as well as a pair of bills aimed at protecting public housing residents from eviction because a family member commits a drug offense. Also worth mentioning is Sen. Jim Webb's (D-VA) National Criminal Justice Commission Act of 2011, which, if it were to pass, would be a feather in the soon-to-be-retiring senator's cap.

On the other side of the issue, the most intense prohibitionist fervor this session is centered around banning new synthetic drugs, with five bills introduced so far to criminalize the possession and trade in either synthetic cannabinoids ("fake weed"), or synthetic stimulants ("bath salts"), or both. Other regressive bills would ban anyone with a drug arrest from owning a gun and require states to drug test welfare recipients. A hearing on welfare drug testing is reportedly coming soon. Conservative Republican-controlled House foreign affairs and national security committees could also see efforts to boost drug war spending in Mexico or other hard-line measures in the name of fighting the cartels.

[To see all the drug policy-related bills introduced so far in Congress, as well as legislation introduced in the states, visit our new Legislative Center.]

While advocates are ready to do battle, the political reality of a deeply divided Congress in the run-up to a presidential election in the midst of deep economic problems means drug policy is not only low on the agenda, but also faces the same Republican House/Democratic Senate gridlock as any other legislation.

"The inertia is not exclusive to sentencing or drug policy reform," said Kara Gotsch of the Sentencing Project. "Nothing is moving. There is such a deadlock between the House and the Senate and the Republicans and the Democrats in both chambers. I don't think failure to move in this Congress is necessarily a sign of limited interest in reform, but the political fighting means nothing moves."

"The House is passing stuff with no expectation it will pass the Senate," said Eric Sterling, executive director of the Criminal Justice Policy Foundation. "The whole Congress right now is in a state of suspended animation, waiting to see whether Obama is reelected or not and whether the Senate goes Republican or not. The gridlock we all see in the headlines around big issues such as taxes and spending filters down to almost every committee and every issue."

And with Republicans in control of the House, the prospects for marijuana law reform in particular are grim in the short term, the former House Judiciary Committee counsel said. "I don't think there is going to be any positive legislative action," Sterling predicted. "The House is not going to take up the medical marijuana bills and it's not going to take up the Frank-Paul legalization bill. They won't even get hearings."

"I don't think any of these marijuana bills will pass with this Congress, but they're very important as placeholders," agreed Morgan Fox, communications director for the Marijuana Policy Project. "As long as those bills are out there, we can keep bringing the issue in front of lawmakers and continue to educate them about this."

Even stalled bills provide opportunities for advancement, Sterling concurred. "That's not to say there isn't important education that can be done, and organizing and encouraging members to cosponsor good legislation. They need to be educated. The test of whether the effort is worthwhile or not is whether it can be passed this session," he offered. "The political stars are not lined up.

Jim Webb at 2007 hearing on incarceration (photo from sentencingproject.org)
Medical marijuana legislation in Congress includes a pair of bills aimed at making the financial system friendlier to dispensaries and other medical marijuana-related businesses, as well as a bill that would reschedule marijuana for prescription use:

  • Introduced by Rep. Jared Polis (D-CO), H.R. 1984, the Small Business Banking Improvement Act of 2011, would protect financial institutions that accept medical marijuana deposits from federal fines or seizures and having to file "suspicious activity" reports. Such threats have prompted major banks to stop doing business with dispensaries.
  • Introduced by Rep. Pete Stark (D-CA), H.R. 1985, the Small Business Tax Equity Act of 2011, would allow dispensaries to deduct expenses like any other business and is designed to avoid unnecessary IRS audits of dispensaries and put an end to a wave of audits already underway.
  • The marijuana rescheduling bill, H.R. 1983, the States' Medical Marijuana Patient Protection Act, would also specifically exempt from federal prosecution people in compliance with state medical marijuana laws. It was introduced by Rep. Barney Frank (D-MA).

"We're having our grassroots support all three pieces of legislation, but our primary thrust is H.R. 1983," said Kris Hermes, spokesman for Americans for Safe Access. "It's tough to get people engaged at the federal level, but we've mounted a social media campaign and want to promote the bill through Facebook and other methods, getting some viral participation in something that should be important for most patients around the country."

Part of the group's difficulty in getting members to focus on Congress is because they are busy fending off assaults at the state and local level, said Hermes. "We've had many instances of state officials doing an about-face on implementation of state laws or further restricting them, so the battleground has become very focused and localized," he noted.

"That takes energy away from what's going on at the federal level, and that's the real tragedy because it's the federal government that's at the root of all the opposition and tension taking place at the local level," Hermes said, pointing to this year's spate of threatening letter from US Attorneys to elected officials. "Having to fight this locally takes energy away from what's going on at the federal level."

Aaron Smith of the National Cannabis Industry Association, the recently formed trade association for marijuana businesses, said his group was focused on the financial bills. "I'm not holding my breath on the Republicans in the House, but the very introduction of these bills is progress," he said. "For the first time, we're actually seeing some of the industry's issues addressed. We think we'll see more traction for these bills than the broader legalization issue. There's already an industry clamoring for regulation, and federal laws are getting in between states and businesses in those states. We will be seeing state officials supporting these reforms. It's hard to write a check to the IRS or state treasuries when you can't have a banking account."

While the association is not predicting passage of the bills this session, it will be working toward that goal, Smith said. "We can get more cosponsors and we will be working to raise awareness of the issue," he said. "Just a year ago, no one even knew about these problems, now they are being addressed, and that's progress in itself."

But Congress is not the only potential source of relief for the industry, Smith said. "It would be helpful if we could get a memo from the Department of the Treasury clarifying that businesses licensed under their respective state laws are not a banking risk," he continued, suggesting that the existence of the bills could help prod Treasury.

While acknowledging the obstacles to reform in the current Congress, Bill Piper, national affairs director for the Drug Policy Alliance, was more upbeat about the state of affairs on Capitol Hill. "I'm super-excited about the level of support for the Frank-Paul marijuana legalization bill," he said. "It has 15 cosponsors now, and when you consider that it is completely undoing federal marijuana prohibition, that's pretty remarkable. Three or four years ago, we couldn't even get anybody to introduce it. And I'm also pleasantly surprised by not only the number of cosponsors, but who they are. They include Reps. John Conyers (D-MI), Charlie Rangel (D-NY), and Barbara Lee (D-CA), three important members of the Congressional Black Caucus, and most recently, Rep. Raul Grijalva (D-AZ), a member of the Hispanic caucus."

In the event that the Democrats retake the House in 2013, Conyers would become chair of the House Judiciary Committee again, Piper noted. "We would have a cosponsor of a bill to end federal marijuana prohibition chairing that key committee," he said. Until then, Piper continued, "while the bill is gaining steam, it is unlikely to get a hearing in this Congress."

If the prospects are tough for marijuana reform in the current Congress, they aren't looking much better for sentencing reform, although the budget crisis could provide an opening, Piper said. "I'm not optimistic about sentencing reform, but DPA is advocating that it be added to the package of spending cuts and bills designed to reduce the deficit over the long term. If they're talking about reforming entitlements and the tax code, they should be talking about reducing unsustainable drug war spending," he argued.

The Sentencing Project's Gotsch said that while the Hill would be difficult terrain for the rest of the session, there is progress being made on the sentencing front. "The Sentencing Commission has been very good, and the Department of Justice has responded favorably to Fair Sentencing Act implementation. Justice supported retroactivity on crack, and it has also reversed course on prosecuting crack cases prior to August 2010," she said.

Even in the Congress, there are small signs of progress, she noted. "I am encouraged by things like federal good time expansion included in the Second Chance Act reauthorization. That has passed the Senate Judiciary Committee, and it even picked up one Republican vote. That's good, and that's a discussion we hadn't had before."

What Gotsch is not getting enough of is hearings, she said. "It's disappointing that there hasn't been more activity regarding hearings, but next month, the Sentencing Commission will hopefully release its mandatory minimum sentencing report, and I know the advocacy community will be pushing the Senate Judiciary Committee to hold hearings on that."

For Sterling, it is money that is going to move things in the current Congress. "According to the latest Sentencing Commission on federal drug cases, 26% of federal drug cases were marijuana cases," he noted. "With a federal drug supply reduction budget of $15.4 billion, you can argue to the Congress that if you were to pass the Frank-Paul legalization bill, you could save about $4 billion a year."

Sterling is making a similar argument to the deficit-tackling congressional Supercommittee about federal crack cocaine prosecutions. "I argue to them that if they eliminated federal crack cocaine prosecutions, which account for about 20% of federal drug cases, they could save $3.5 billion a year," he said. "Crack is made and sold locally; it shouldn't be a federal case. That should be reserved for people like Mexican cartel leaders."

But while Sterling's argument is logical, he is not sanguine about the prospects. "We could save billions of dollars a year, but I don't think something that gets translated as letting dope dealers out of prison is going to get very far. Still, it's a contemporary argument, and the money is real money. What is clear is that these expenditures are a waste; they're not keeping drugs out of the hands of the community or reducing the crime in the community, and the money could be better spent on something else."

Budget battles offer potential openings to drug reform foes as well. House Republicans are using budget bills to attempt to kill reforms they didn't like, such as opening up federal AIDS funding streams to needle exchange programs, said Hilary McQuie of the Harm Reduction Coalition.

"We have to fight this constantly in the House now," she said. "They're reinserting all these bans; they even put a syringe exchange ban rider in the foreign operations budget bill, so that's a new front, and we can't even fight it in the House. That means we have to make sure the Senate is lined up so these things can be fixed in conference committee. It feels to me like we can't make any progress in Congress right now."

McQuie said, though, that Congress isn't the only game in town. "We're looking less to Congress and more to the regulatory bodies," she said. "Obama's appointments have been pretty good, and just last week we had SAMHSA coming out with guidance to the state about applying for substance abuse block grants. This is the first big piece of money going out with explicit instructions for funding syringe exchange services. Even in this political atmosphere, there are places to fight the fight."

Where the Congress is likely to be proactive on drug policy, it's likely to be moving in the wrong direction. The ongoing panic over new synthetic drugs provides a fine opportunity for politicians to burnish their drug warrior credentials, and legislation to ban them is moving.

"I'm pessimistic about those stupid bills to outlaw Spice and bath salts," said Piper. "One bill to do that just sailed through the House Commerce Committee, and we're hoping it at least goes through Judiciary. The Republicans definitely want to move it, it went through Commerce without a hearing, and no one opposed it," he explained. "But we're working on it. Given that this is the 40th anniversary of the failed war on drugs, why add another drug to the prohibitionist model?"

"Those bills are going to pass," Sterling bluntly predicted. "There may be some quibbling over sentencing, but there's simply no organized constituency to fight it. DPA and the ACLU are concerned about civil liberties, but I don't think that's going to have much of an impact. I'd be very surprised if more than a handful of liberals vote against this."

That may not be such a bad thing, he suggested. "I'm quite willing to say that people who use these things should not be punished, but I'm not sure I want to defend the rights of people to sell unknown chemicals and call them whatever they want," he said.

Even though the evidence of harm from the new synthetics may be thin, it remains compelling, Sterling said, and few legislators are going to stand up in the face of the "urgent" problem. "Even if you argued that these drugs needed to be studied, the rejoinder is that we are facing a crisis. To challenge these bills is asking more courage of our legislators than our system tolerates."

The remainder of the current Congress is unlikely to see significant drug reform, in large part for reasons that have more to do with congressional and presidential politics than with drug policy. But that doesn't mean activists are going to roll over and play dead until 2013.

"People should continue to pressure members of Congress to get on the Frank-Paul legalization bill," urged Piper. "The more cosponsors we get, the more it helps with passing legislation at the state level, and it also helps with getting media on the issue and making it more likely that the bill will get a hearing. That's a top priority for us."

The budget issue also needs to stay highlighted, Piper said. "Whether it's Democrats or Republicans in charge, Congress is going to make cuts, and they should definitely be pressured to cut the drug war. We want the drug war on the chopping block. This is a unique historical opportunity with the recession and the focus on the budget cuts. We have to re-frame the drug war as not only failed, but too expensive to continue."

Washington, DC
United States

Chronicle Book Review: Drugs and Drug Policy

Drugs and Drug Policy: What Everyone Needs to Know, by Mark Kleiman, Jonathan Caulkins, and Angela Hawken (2011, Oxford University Press, 234 pp., $16.95 PB)

http://www.stopthedrugwar.org/files/drugs_and_drug_policy.jpg
Mark Kleiman isn't real popular among the drug reform set. The UCLA professor of public policy is no legalizer, and even though he's too much of an evidence-minded academic to be a wild-eyed drug warrior, he still seems to have an unbecoming fondness for the coercive power of the state. Kleiman, who gets top-billing over coauthors Jonathan Caulkins of Carnegie Mellon and Angela Hawken at Pepperdine, also ruffles reformers' feathers with unnecessary snideness and snark.

But I watched Kleiman address Students for Sensible Drug Policy conventions a couple of times, and I thought it was a good thing, a very useful jolt to the group-think that can grip any gathering of congregants committed to a cause. I thought having the students have to hear the arguments of a leading academic thinker on drug policy who, while not "the enemy," was not especially saying what the average SSDPer wanted to hear, was salubrious for their critical thinking skills. I still think so.

In Drugs and Drug Policy, Kleiman and his coauthors continue with the occasional jibes aimed at the drug reform movement, at times reach conclusions at odds with my own, but also serve up a surprisingly chewy work of drug policy wonkery in delicious bite-size chunks. The innovative format, something like a series of FAQs organized within broader chapters -- "Why Have Drug Laws?" "How Does Drug Law Enforcement Work?" "What Treats Drug Abuse?" "Can Problem Drugs Be Dealt With at the Source?" -- allows us to unpack that all-encompassing monster called "drug policy" one subset at a time, and for that achievement alone, is worthy of praise. That it manages to cover so much ground in a paltry 234 pages is all the more laudable.

Overall, Drugs and Drug Policy is smart, reasonable, and thoughtful. It wants policies based on evidence and it advocates for some intelligent alternatives to current policies. It recognizes the utility of needle exchanges, safe injection sites, and opiate maintenance, even as it complains that "harm reduction" has been hijacked by legalizers. It explains that most people who use drugs -- even those diagnosable as suffering from substance abuse disorders -- will quit using drugs themselves without recourse to treatment. And it even allows that drug use can have beneficial effects, even if it doesn't do so until the seventh chapter.

But Kleiman et. al dismiss decriminalization as unlikely to have a big impact on the social fiscal burden of drug law enforcement because, even though it doesn't appear to have much impact on consumption, drug consumers are not, for the most part, filling our prisons -- drug dealers are. While they do concede that not criminalizing otherwise law-abiding citizens could have "significant benefits," they seem to underplay the negative, life-long impact of a criminal drug record on one's life prospects.

In fact, they seem all too comfortable with maintaining the pernicious role of the criminal justice system in drug policy even as they recognize that enforcing the drug laws is "unavoidably an ugly process," with its reliance on snitches, surveillance, and other "intrusive methods" of enforcement. To give them credit, they want smarter drug law enforcement -- concentrating police repression on violent drug dealers while turning a blind eye to discreet dealing, triaging coerced drug treatment spots so they are reserved for the people who could most benefit from them, giving up on interdiction and source country eradication as ineffective -- that might actually reduce the social and fiscal costs of both drug abuse and enforcement, and since drug prohibition isn't going away anytime soon, at least wasting less money on drug war tactics that don't work well should be on the table.

And they reject drug legalization as too scary to experiment with, but seem to imagine it as possible only within a corporate-controlled, heavily-advertised, low-priced scenario similar to that which has accreted around the alcohol industry. Yes, it's probably true that selling cocaine like Coors, would lead (at least initially) to a significant increase in use and problem use, but why does that have to be the only model? A government monopoly similar to the state liquor store model, with reasonable taxes and no corporate pressure to advertise could conceivably allow legalization without the increases in consumption that the authors predict, even though they concede they don't know how large they might be.

Still, when you get to what it is Kleiman et al. would do if they had their druthers, all but the most purist of legalization advocates will find a lot to like. They create three separate lists of recommendations -- a "consensus list" of reforms they think are politically doable now or in the near future, a "pragmatic list" of reforms that would appeal to dispassionate observers but could raise the hackles of moralists, and a "political bridge too far list" of reforms too radical for mainstream politicians to embrace.

The "consensus list" includes expanding opiate maintenance therapy, encouraging evidence-based treatment, early intervention by the health care system, encouraging people to quit on their own (as opposed to being "powerless"), relying less on interdiction, ending the charade that alternative development is drug control, and concentrating drug enforcement on reducing violence and disorder, as well as smarter, more effective coerced treatment in the legal system. If we saw the drug czar's office produce a National Drug Control Strategy with these recommendations, we would consider that a great victory. It ain't legalization, but its headed in a more intelligent, more humane direction.

The "pragmatic list" includes recommendations to lower the number of drug dealers behind bars, not reject harm reduction even if it's been "hijacked," stop punishing former dealers and addicts, reduce barriers to medical research on illegal substances, and be open-minded about less harmful forms of tobacco use.

The authors don't neglect alcohol and tobacco -- the two most widely-used drugs -- and that is really evident in their "political bridge too far" recommendations. The first three items there are aimed squarely at reducing alcohol consumption and its ill effects. They also argue for the legalization of individual or collective marijuana cultivation, a sort of legalization without the market, increased study of the non-medical benefits of drugs, and increasing cigarette taxes in low tax states.

I think Drugs and Drug Policy needs to be read by anyone seriously interested in drug policy reform. It hits almost all the bases, and it's well-informed, provocative, and challenging of dogmatic positions. You don't like the authors' conclusions? Refute them. It'll be good for you.

Life After the War on Drugs: Reviewing Past and Present Policies with an Eye Toward Legal Reform

University of the District of Columbia David A. Clarke School of Law
2011 Law Review Symposium

David A. Clarke School of Law
 

"Life After the War on Drugs: Reviewing Past and Present Policies With an Eye Toward Legal Reform"


Introduction (10:00 – 10:15 a.m.)
• John Brittain, Professor, UDC-DCSL, Chief Counsel and Senior Deputy Director of the Lawyers' Committee for Civil Rights Under Law (2005-2009)

Panel 1: Drug Policy at Home and Abroad (10:15 a.m. – 12:00 p.m.)
• Eric Sterling, Advisory Board Member, Law Enforcement Against Prohibition (LEAP)
• Brooke Mascagni, PhD Candidate, University of California, Santa Barbara
• Jordan Blair Woods, PhD Candidate, Cambridge University (U.K.), J.D. University of California Los Angeles

Lunch (12:00 – 1:00 pm)
• Lunch Keynote Speaker: Ronald C. Machen, Jr., United States Attorney for the District of Columbia

Panel 2: Conflicts between State and Federal Drug Laws (1:00 – 3:30 p.m.)
• Andrew Ferguson (Moderator), Professor, UDC-DCSL, Public Defender Service of the District of Columbia (2004-2010)
• Robert Hildum, Director, D.C. Dept. of Youth Rehabilitation Services (2010)
• Sumeet H. Chugani, Esq. and Xingjian Zhao, Esq., Diaz, Reus & Targ, LLP (Miami, FL)
• Alex Kreit, Director, Center for Law and Social Justice, Thomas Jefferson School of Law (San Diego, CA)

Panel 3: The Unknown Effects of the War on Drugs (3:45 – 5:00 p.m.)
• Brian Gilmore, Director, Michigan State University College of Law Housing Clinic
• Ken Lammers, Deputy Commonwealth Attorney, County of Wise and City of Norton in Virginia
• Michael Liszewski, Board of Directors, Students for Sensible Drug Policy

Cocktail Reception (5:10 – 6:00 p.m.)

Plenary Panel: Life After the War on Drugs (6:00 – 9:00 p.m.)
• Keynote Speaker: Wade Henderson, President and CEO, The Leadership Conference on Civil and Human Rights
• Jasmine Tyler, Deputy Director of National Affairs, Drug Policy Alliance
• Mark Osler, Professor, University of St. Thomas School of Law (Minneapolis, MN)
• The Honorable Arthur L. Burnett, Sr., National Executive Director, National African-American Drug Policy Coalition
• Dr. Faye Taxman, Director, Center for Advancing Correctional Excellence, George Mason University

The event is free and open to the public, but registration is limited. To register, see http://www.law.udc.edu/events/event_details.asp?id=136549.

For any questions, please contact Symposium Editor Leila Mansouri at Leila.Mansouri@udc.edu.

Date: 
Thu, 03/24/2011 - 10:00am - 9:00pm
Location: 
4200 Connecticut Avenue, NW University of the District of Columbia David A. Clarke School of Law, Windows Lounge: Building 38, 2nd Floor
Washington, DC 20008
United States

The 2012 Federal Drug Budget: More of the Same [FEATURE]

The Obama administration released its a href="http://www.whitehousedrugpolicy.gov/policy/12budget/fy12Highlight.pdf">proposed 2012 National Drug Control Budget Monday and, despite President Obama's statement just over two weeks ago that the federal government needed to "shift resources" to have a smarter, more effective federal drug policy emphasizing public health approaches, there is little sign of any resource shifting.

Drug War Autopilot and Co-Autopilot: ONDCP Director Gil Kerlikowske with President Obama
Although budget documents said the administration seeks "a balanced approach" of prevention, treatment, and domestic and international law enforcement, law enforcement continues to get the lion's share of federal drug dollars. Of the more than $26 billion allocated for federal drug control efforts, nearly 60% would go to "supply reduction" (read: domestic and international drug law enforcement and military interdiction) and only 40% would go to treatment and prevention.

And in a time when the clamor for deficit reductions and budget cuts grows louder by the day, the Obama administration drug budget actually increases by 1.3% over 2010. That means it could be in for a rough ride when congressional appropriations committees get their hands on it, although no Republican leaders have yet commented on it.

[Editor's Note: All year-to-year comparisons are to Fiscal Year 2010 because Congress still hasn't passed a FY 2011 budget.]

On the other hand, at least the administration is being honest. Since 2004, the Office of National Drug Control Policy (ONDCP -- the drug czar's office), which produces the drug budget, under drug czar John Walters had used accounting legerdemain to substantially understate the real costs of federal drug control by not including the drug component in the work of a number of different federal agencies. Using the understated figures, this year's drug budget would have appeared to have been only $15.3 billion instead of the more accurate $26.2 billion, with a false appearance of equality between supply-side and demand-side funding.

[Editor's Note: Bush-era drug czar John Walters stated directly, in response to a question I asked at an event, that they omitted budget items that included drug control but were not 100% about drug control -- claiming that made the numbers "more accurate," but not explaining how that made sense in any way. -DB]

"At least they finally got around to fixing the accounting problem," said Bill Piper, national affairs director for the Drug Policy Alliance."It took them five years after Congress told them to fix it, but at least they are showing the true cost of things, like incarceration."

But neither Piper nor representatives of other drug reform groups had much else nice to say about the budget. "It's very much like last year's budget, with most money going to ineffective supply side programs and not enough going to treatment," Piper said. "You have the president and the drug czar talking about treating drug abuse as a public health issue just weeks ago, but their budget continues to treat it as a law enforcement and military issue."

"I don't understand how the president can tell us with a straight face that he wants to treat drugs as a health issue but then turn around just a few weeks later and put out a budget that continues to emphasize punishment and interdiction," said Neill Franklin, executive director of Law Enforcement Against Prohibition and a former narcotics officer in Baltimore. "The president needs to put his money where his mouth is. Right now it looks like he's simply all talk and no game."

"I see this similarly to Obama's approach on needle exchange and crack sentencing -- the president supported those reforms verbally, but did nothing else to help them at first, even when he had the opportunity," said David Borden, executive director of StoptheDrugWar.org, publisher of this newsletter. "But when Congress was ready to take them on, the administration provided enough support to get them through. Obama has also supported the idea of shifting the drug budget's priorities, but again has done nothing whatsoever to make it happen. Maybe what he wants is for Congress to do the heavy lifting on this as well. If so, our movement's task is to propose a politically viable new version of the budget that does change the priorities, to build support for it in Congress, and then look for the administration to get on board."

"We're definitely going to be focused on cutting funding to the drug war during the congressional appropriations process," said Piper. "We're already meeting with both Republicans and Democrats to increase support for cutting funding to the Byrne grants, the media campaign, and other ineffective drug war programs. I don't think there are any sacred cows now, and our goal is to get the drug war on the chopping block along with everything else."

While there are individual programs that saw cuts in both the treatment and prevention side and the law enforcement side, only in the realm of international anti-drug assistance was there an overall decrease in spending. Although the budget funds foreign assistance at $2.1 billion, that is $457 million less than the 2010 budget, a decrease of 17%. The decrease results from the winding down of Plan Colombia funding, a shift from expensive technologies for Mexico to more programmatic aid, and the re-jiggering of some of the Afghanistan anti-drug spending to be counted as "rule of law" spending.

Proposed spending on interdiction is set at $3.9 billion, an increase of $243 million over 2010 levels. The departments of Defense and Homeland Security account for the bulk of that spending, which includes an increase of $210 million for border security and port of entry facilitation on the US-Mexico border.

But international anti-drug aid and interdiction spending are dwarfed by domestic drug law enforcement, which would gobble up $9.5 billion under the Obama drug budget, an increase of $315 million over 2010 levels, or 3.4%. Unsurprisingly, the single largest domestic law enforcement expenditure is $3.46 billion to incarcerate federal drug war prisoners.

[Editor's Note: In the budget, the authors refer to high federal corrections costs because of the high number of drug war prisoners -- they make up well over half the more than 200,000 federal prisoners -- as "a consequence of drug abuse," when those costs are more than anything a consequence of public policy decisions made over decades.]

The Office of Justice Grants program, which includes the Byrne Justice Assistance Grants used to fund anti-drug multi-jurisdiction law enforcement task forces, would be slashed substantially, from $3.52 billion in 2010 to $2.96 billion in 2012, but on the other hand, the Justice Department 2012 budget contains $600 million to hire and retain 4,500 new police officers.

"It's encouraging that they cut funding for the Byrne grants," said Piper, "but they're increasing funding for the COPS program. The money is still going to law enforcement, but cutting those grants is a step in the right direction."

There are a few law enforcement side losers in addition to the Byrne grants. The DEA budget is down slightly, from $2.05 billion in 2010 to $2.01 billion in 2012, but that reflects supplemental spending for the southwest border that was included in 2010. The High Intensity Drug Trafficking Area (HIDTA) program, which has evolved into a prime example of pork, saw its funding slashed to $200 million, down from $239 million.

And while overall treatment and prevention funding was up slightly, by 1% and 8% respectively, those increases are relatively slight, and there are some losers there, too. The Substance Abuse and Mental Health Services Administration (SAMHSA) Prevention grant program would decline from $565 million in 2010 to $550 million in 2012, Drug Free Communities funding would decline from $95 million to $89 million, and substance abuse treatment Medicaid grants to the states would decline from $3.78 billion to $3.57 billion.

On the plus side, spending for the Successful, Safe, and Healthy Students grant program would increase from $177 million to $267 million, Medicare treatment spending would increase by about 10% to $1.463 billion, Substance Abuse Treatment Block Grant funding would increase fractionally, and reentry funding under the Second Chance Act would increase from $30 million to $50 million.

The much criticized ONDCP youth media campaign would remain at $45 million, and the mostly praised drug court program would also remain unchanged, at $57 million.

All in all, despite slight changes in emphasis, the 2012 federal drug control budget is much of a muchness with previous drug budgets, despite the Obama administration's lip service about changing priorities and embracing the public health paradigm.

"Everyone wants to cut federal spending somehow," said Piper. "It seems that cutting the drug war would be an easy way to do that without cutting funds to the poor, to education, and other desirable social programs. Obama has said how sad he was to have to cut programs he likes, but he probably could have saved those programs by cutting funding for the drug war."

Washington, DC
United States

Republican Lawmakers Shifting Tough-On-Crime Stance As State Budget Problems Multiply

In no state is the philosophical U-turn more abrupt than in Oklahoma, where last year the Legislature was barreling in the opposite direction. New Republican Speaker of the House Kris Steele is expected to unveil a package of proposals that would divert thousands of nonviolent lawbreakers from the prison system and ramp up paroles. Similar crash prison reductions are going on from coast to coast. Michigan has shuttered 20 correctional facilities and slashed spending by nearly 7 percent. South Carolina expects to reduce its inmate numbers by 8 percent by putting drug dealers, burglars and hot check writers into community programs instead of behind bars.
Publication/Source: 
Los Angeles Times (CA)
URL: 
http://www.latimes.com/news/nationworld/nation/wire/sns-ap-us-broken-budgets-prison-problems,0,2779184.story

Barriers to Ex-Offender Employment Could Cost the Nation at Least $57 Billion

According to a study from the Center for Economic and Policy Research's senior economist John Schmitt, ex-offenders' barriers to employment lowers the nation's employment on average by 1.5 million to 1.7 million workers. Multiply that number by the average output that these workers would be putting into the economy, if they were employed, and the loss totals at least $57 billion, he said. This figure is growing as more of the hundreds of thousands of people put into jail during the prohibitionist war on drugs in the 1980s and 1990s are released.
Publication/Source: 
Los Angeles Times (CA)
URL: 
http://latimesblogs.latimes.com/money_co/2010/11/ex-offender-and-employment.html

Iowa Drugs Appeal Case Headed to Supreme Court

Location: 
IA
United States
Two attorneys say they'll take an Iowa case before the nation's highest court next week that could alter how federal judges sentence convicts after appeals. The issue is if judges can weigh a convict's efforts at rehabilitation while an appeal is pending.
Publication/Source: 
Chicago Tribune (IL)
URL: 
http://www.chicagotribune.com/news/chi-ap-ia-methdealer-suprem,0,1450079.story

Growth of Ex-Offender Population in United States Is a Dramatic Drag on Economy (Press Release)

For Immediate Release:November 15, 2010
Contact: Alan Barber, (571) 306-2526

Washington, D.C.- Three decades of harsh criminal justice policies have created a large population of ex-offenders that struggle in the labor market long after they have paid their debts to society, according to a new report from the Center for Economic and Policy Research (CEPR). Because prison records and felony convictions greatly lower ex-offenders' chances of finding work, the United States loses between $57 billion and $65 billion a year in lost output.

“It isn't just that we have the highest incarceration rate in the world, we have created a situation over the last 30 years where about one in eight men is an ex-offender,” said John Schmitt, a Senior Economist at CEPR and a co-author of the report.

The new report, “Ex-offenders and the Labor Market,” found that in 2008 there were between 5.4 million and 6.1 million ex-prisoners and between 12.3 million and 13.9 million ex-felons in the United States. Over 90 percent were men.

In 2008, about one in 33 working-age adults was an ex-prisoner, and about one in 15 working-age adults was an ex-felon. Among working-age men in that same year, about one in 17 was an ex-prisoner and one in eight was an ex-felon.

Because ex-offenders face substantial barriers to employment, the authors estimate that the large ex-offender population in 2008 lowered employment that year by the equivalent of 1.5 million to 1.7 million workers.

"The rise in the ex-offender population overwhelmingly reflects changes in the U.S. criminal Justice system, not changes in underlying criminal activity," says Schmitt. "We incarcerate an astonishing share of non-violent offenders, particularly for drug-related offenses. We have far better ways to handle these kinds of offenses, but so far common sense has not prevailed."

The report warns that in the absence of reforms to the criminal justice system, the share of ex-offenders in the working-age population will rise substantially in coming years, increasing the magnitude of employment and output losses estimated for 2008.

###

The Republican House and Drug Reform: The Good, the Bad, and the Ugly [FEATURE]

Last week, a resurgent Republican Party retook control of the US House of Representatives, giving the Democrats a drubbing the likes of which has not been seen for decades. The Democrats lost 61 seats, seeing their side sink to 189 seats to the Republicans' 240. They needed 218 to take over again.

The change in control of the House has some serious drug policy implications. There's bad news, but maybe also some good news.

Reform measures passed in the current Congress, such as repealing the bans on federal funding of needle exchange programs and implementation of the Washington, DC, medical marijuana program, could see attempts to roll them back. And pending reforms efforts, such as the battle to repeal the HEA student loan provision, are probably dead. Reform friendly Democratic committee chairs, who wield considerable power, have been replaced by hostile Republicans.

But the incoming Republicans made slashing the deficit and cutting the federal budget a winning campaign issue for themselves, and will be looking for programs they can cut or eliminate. That could open the door to hacking away at programs that support the ongoing prosecution of the drug war, but it could also open the door for cuts in prevention and treatment programs.

As the Chronicle noted here earlier this week, it's not just Tea Party types who want to wield the budget ax. The mainstream conservative Heritage Foundation issued a report just before election day laying out a whopping $434 billion in federal budget cuts, including eliminating the Office of National Drug Control Policy, the drug task force-funding Justice Assistance Grant (JAG, formerly the Byrne grant program) program, and the Safe and Drug Free Schools and Communities state grant program.

"Budgetary issues is where I'm most optimistic," said Bill Piper, veteran national affairs director for the Drug Policy Alliance. "Given the fiscal climate, there could be real cuts in the federal budget. Next year is probably an unprecedented opportunity to de-fund the federal drug war. These new Republicans are a different breed—anti-government, anti-spending, pro-states' rights, and some are proven to be prone to bucking the leadership. If the Republican leadership votes to preserve the drug war, they may rebel," he said.

"We can go after the Byrne grant program," Piper enthused. "That's a very important deal. If we can cut off drug war funding to the states, the states won't be able to afford their punitive policies anymore. During the recession in the Bush administration, when the administration was cutting money to the states, a lot of states passed reform measures because they couldn't afford to lock people up. This time, the federal government has been bailing out state criminal justice systems, but if we can cut or eliminate Byrne grants, the states won't have money for their drug task forces and imprisoning people. Then they will have to consider reforms like cutting sentences and making marijuana possession an infraction."

"Sentencing reform on budgetary grounds is possible," said Kara Gotsch, director of advocacy for the Sentencing Project. "From our perspective, that is a way to reduce government spending. If you want to reduce drug war spending, you reduce costs by investing in prevention and substance abuse programs. That will be part of our talking points, but the reality is, to be successful they're going to have to be bipartisan."

Eric Sterling, former House Judiciary Committee counsel and current head of the Criminal Justice Policy Foundation was less sanguine than either Piper or Gotsch about the urge to cut the deficit leading to progress in drug reform. "The prospect of saving money leading to criminal justice and drug policy reform is remote," said Sterling. "In state legislatures where they have to balance the budget, everyone recognizes what has to happen. But in Congress, they know there is still going to be a deficit."

Sterling also questioned just how different the Republican freshman class will be from traditional Republicans. "That's a big question mark," he said. "They are younger and bring with them different experiences about drug policy or marijuana in particular, but most of these men and women won by using traditional themes that most incumbent Republicans used, too. I think for them, cracking down on drugs and crime will have more value than trying to save money by funding diversion or correctional programs that aren't about harsh punishment."

But Piper remained upbeat. "Next year is probably an unprecedented opportunity for the movement to defund the drug war. The stars are aligning. A lot of tax groups are already on record for cutting some of these programs," he noted. "Given the fiscal climate, we could see considerable cuts in the federal budget. The type of Republicans coming into office, as well as Obama's own need to show he can practice fiscal discipline, means a real chance to cut or eliminate some of those programs," he said. "The down side is that funding for prevention and treatment is likely to come under fire, too."

Rep. Lamar Smith (R-TX) -- no friend of drug reform.
While budget battles will be fought in appropriations committees, criminal justice issues are a different matter. One of the most striking changes  comes in the House Judiciary Committee, where pro-drug reform Democrats like chairman John Conyers (D-MI) and Subcommittee on Crime, Terrorism, and Homeland Security chair Bobby Scott (D-VA) are being replaced by the likes of Rep. Lamar Smith (R-TX), who will head the Judiciary Committee. Smith, a conservative old school drug warrior, was the only congressman to speak up against passage of the bill to reduce the disparity in crack and powder cocaine sentences.

He also authored a bill this fall that would have made it a federal offense for US citizens to plan to commit acts outside the US that would violate US drug laws. While that bill was allegedly aimed at large drug trafficking organizations, it could have made federal criminals out of college students making plans to visit the coffee shops of Amsterdam. He took to Fox News last month to lambaste the Obama administration as insufficiently tough on marijuana law enforcement, a clip he displays on his web site (scroll over the small video screens; the title will pop up).

"The fact that Rep. Smith is going to be the chair will definitely have an impact," said Gotsch. "He was the only vocal opposition to the crack cocaine sentencing reform, and the fact that he is now going to be chair is discouraging. It indicates that he won't be thoughtful about sentencing reforms for low level drug offenders."

"The Democratic committee chairs were good on drug policy and unlikely to advance bad drug war bills," said Piper. "Now, with Conyers and Scott gone and Lamar Smith in charge, we can expect stuff like Smith's foreign drug conspiracy bill to come out of that committee."

"You couldn’t find bigger champions for reform than Scott and Conyers," said Gotsch. "We won't have them as chairs now; that's probably the biggest disappointment to our community."

"Smith has been quite out there in his attacks over the drug issue," said Sterling. "My hunch is that we will take advantage of the political attractiveness of the drug issue to try to have both oversight hearings and legislation that would be embarrassing to Democrats."

And don't expect too much from the Democrats, either, he added. "The Democratic caucus is going to be more reluctant to deal with the drug issue in a progressive way than it has been," said Sterling. "They see it as a distraction from the heart of the message they need to bring to retake power in 2012."

With people like Smith holding key House committee positions, the drug reform agenda is likely to stall in the next Congress. Instead, reformers will be fighting to avoid reversing earlier gains.

"In terms of passing good things, there probably wasn’t a lot more that was going to happen with Democrats before 2012," said Piper. "The important low hanging fruit of overturning the syringe ban, the DC medical marijuana ban, and the crack sentencing bill had already gotten through. We might have been able to achieve repeal of the HEA drug provision, but probably not now."

The drug reform movement's job now will be not only blocking bad legislation, but also fighting to prevent a rollback of drug reform victories in the current Congress, such as the repeal of the bans on syringe exchange funding and implementing the Washington, DC, medical marijuana law, said Piper. 

"They're unlikely to go backwards on crack, but the syringe ban and the DC medical marijuana ban were both repealed with some, but not a lot, of Republican support," he said. "The syringe ban repeal barely passed, and that was in a Congress dominated by Democrats. Will they try to restore the syringe funding ban and overturn DC's medical marijuana program? That's our big fear. Hopefully, we can scrape up enough votes to defeat in the House, or stop it on the Senate side," he said.

Piper also dared to dream of an emerging Republican anti-drug war caucus. "We don't know who these new Republicans all are, but some have probably been influenced by Ron Paul (R-TX)," he said. "If only 10 of them stand up against the drug war, that's a huge opportunity to raise hell in the Republican caucus. Almost a third of Republican voters want to legalize marijuana, and that's an opportunity for us, too. Maybe there will be Republicans we can work with and create a truly bipartisan anti-drug war coalition in Congress. That's a foothold."

For Piper, the future looks stormy and cloudy, but "the silver lining is in appropriations fights and opportunities to organize an anti-drug war movement in the Republican caucus. We just have to play defense on a bunch of stuff," he said. 

"The activist community is going to have to figure out what the recipe for our lemonade is," advised Sterling. "That requires first a redoubled effort at organizing, using themes such as the wise stewardship of the scarce resources we have, and what works and what is effective," he said.

"It also requires mobilizing people not involved in this issue before, whether it's the business community or people who see their rice bowls been broken by the Republican approach," Sterling continued. "Teachers, nurses, people asking how come the part of the public work force this is protected is the police and the police guards. Drug policy reform activists have to think about what are the alliances they can make in this time of public resource scarcity."

Washington, DC
United States

Rockefeller Repeal Leader Wins NY Democratic AG Nomination

New York state Sen. Eric Schneiderman, author of last year's Rockefeller drug law reform legislation, won the Democratic Party nomination for state attorney general in last week's primary election. Scheiderman won 34% of the vote in a five-person race, besting Nassau County prosecutor Kathleen Rice, who came in second with 32%.

Eric Schneiderman
He will face Republican nominee Staten Island prosecutor Dan Donovan in the November 2 general election. In his victory speech, Scheiderman vowed to follow "the same aggressive, progressive approach" as current Democratic Attorney General Andrew Cuomo, who is favored to win the governor's race.

While all five Democratic attorney general candidates vowed to take a hard line on public corruption, help prevent another Wall Street crisis, and protect New Yorkers from terrorism, Schneiderman also played up his drug reform credentials.

On his issues page, Schneiderman touts his authorship of Rockefeller reform legislation, adding that the laws "were not only unfair and unsustainable, but an economic and moral threat to every New Yorker," and advertisements running during the campaign cited it as well. The New York Times also cited Schneiderman's championing of Rockefeller reform among its key reasons for endorsing him in the primary.

Scheiderman goes into greater detail in his Agenda for the Office of New York Attorney General. In addition to touting his role in Rockefeller law reform and in cosponsoring the law that forbids law enforcement agencies from keeping files on innocent people who have been stopped and frisked, Schneiderman vows to monitor and report on stop and frisk searches and to examine the criminal justice system for system-wide biases. He also promises to ease rehabilitation and reentry for ex-convicts and to promote a color-blind criminal justice system.

(This article was published by StoptheDrugWar.org's lobbying arm, the Drug Reform Coordination Network, which also shares the cost of maintaining this web site. DRCNet Foundation takes no positions on candidates for public office, in compliance with section 501(c)(3) of the Internal Revenue Code, and does not pay for reporting that could be interpreted or misinterpreted as doing so.)

NY
United States

Drug War Issues

Criminal JusticeAsset Forfeiture, Collateral Sanctions (College Aid, Drug Taxes, Housing, Welfare), Court Rulings, Drug Courts, Due Process, Felony Disenfranchisement, Incarceration, Policing (2011 Drug War Killings, 2012 Drug War Killings, Arrests, Eradication, Informants, Interdiction, Lowest Priority Policies, Police Corruption, Police Raids, Profiling, Search and Seizure, SWAT/Paramilitarization, Task Forces, Undercover Work), Probation or Parole, Prosecution, Reentry/Rehabilitation, Sentencing (Alternatives to Incarceration, Clemency and Pardon, Crack/Powder Cocaine Disparity, Death Penalty, Decriminalization, Drug Free Zones, Mandatory Minimums, Rockefeller Drug Laws, Sentencing Guidelines)CultureArt, Celebrities, Counter-Culture, Music, Poetry/Literature, Television, TheaterDrug UseParaphernalia, ViolenceIntersecting IssuesCollateral Sanctions (College Aid, Drug Taxes, Housing, Welfare), Violence, Border, Budgets/Taxes/Economics, Business, Civil Rights, Driving, Economics, Education (College Aid), Environment, Families, Free Speech, Gun Policy, Human Rights, Immigration, Militarization, Money Laundering, Pregnancy, Privacy (Search and Seizure, Drug Testing), Race, Religion, Sports, Women's IssuesMarijuana PolicyGateway Theory, Hemp, Marijuana -- Personal Use, Marijuana Industry, Medical MarijuanaMedicineMedical Marijuana, Science of Drugs, Under-treatment of PainPublic HealthAddiction, Addiction Treatment (Science of Drugs), Drug Education, Drug Prevention, Drug-Related AIDS/HIV or Hepatitis C, Harm Reduction (Methadone & Other Opiate Maintenance, Needle Exchange, Overdose Prevention, Safe Injection Sites)Source and Transit CountriesAndean Drug War, Coca, Hashish, Mexican Drug War, Opium ProductionSpecific DrugsAlcohol, Ayahuasca, Cocaine (Crack Cocaine), Ecstasy, Heroin, Ibogaine, ketamine, Khat, Marijuana (Gateway Theory, Marijuana -- Personal Use, Medical Marijuana, Hashish), Methamphetamine, Nicotine, Prescription Opiates (Fentanyl, Oxycontin), Psychedelics (LSD, Mescaline, Peyote, Salvia Divinorum), Synthetic Drugs (Mephedrone, Synthetic Cannabinoids)YouthGrade School, Post-Secondary School, Raves, Secondary School